Guardant Health's Liquid Biopsy Test Wins FDA Nod for Boehringer's Lung Cancer Drug
Event summary
- FDA approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, a targeted therapy for HER2-mutant advanced non-small cell lung cancer (NSCLC).
- Guardant360 CDx is a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a blood draw to identify eligible patients for HERNEXEOS treatment.
- This is the 27th CDx indication for Guardant360 CDx across multiple tumor types globally.
- HERNEXEOS received accelerated approval based on objective response rate and duration of response, with continued approval contingent upon confirmatory trial results.
The big picture
This FDA approval solidifies Guardant Health's position in the precision oncology space, particularly in non-small cell lung cancer treatment. The partnership with Boehringer Ingelheim underscores the growing importance of liquid biopsy tests in identifying actionable mutations, enabling more targeted and timely cancer therapies. With over 300 million covered lives, Guardant360 CDx's broad payer coverage further enhances its clinical utility and market potential.
What we're watching
- Market Expansion
- How Guardant Health will leverage this approval to expand its market reach and increase adoption of Guardant360 CDx.
- Regulatory Dynamics
- Whether the accelerated approval pathway for HERNEXEOS will impact the timeline for confirmatory trial results and subsequent market dynamics.
- Competitive Positioning
- The pace at which Guardant Health can differentiate itself from competitors in the liquid biopsy space with this strategic partnership.
Related topics